Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, Hirata S, Okano Y, Sato S, Yasuoka H, Kuwana M, Ishii T, Kameda H, Kojima T, Nishi Y, Mori M, Miyagishi H, Toshima G, Sato Y, Tsai WC, Takeuchi T, Kaneko Y; MIRACLE Study Group; MIRACLE study Group. Tamai H, et al. Among authors: hirata s. Ann Rheum Dis. 2024 Oct 4:ard-2024-226350. doi: 10.1136/ard-2024-226350. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39366722
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.
Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, Hirata S, Okano Y, Sato S, Yasuoka H, Kuwana M, Ishii T, Kameda H, Kojima T, Taninaga T, Mori M, Miyagishi H, Sato Y, Tsai WC, Takeuchi T, Kaneko Y; MIRACLE study collaborators. Tamai H, et al. Among authors: hirata s. Lancet Rheumatol. 2023 Apr;5(4):e215-e224. doi: 10.1016/S2665-9913(23)00070-X. Lancet Rheumatol. 2023. PMID: 38251524 Clinical Trial.
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T. Kaneko Y, et al. Among authors: hirata s. Ann Rheum Dis. 2016 Nov;75(11):1917-1923. doi: 10.1136/annrheumdis-2015-208426. Epub 2016 Jan 5. Ann Rheum Dis. 2016. PMID: 26733110 Free PMC article. Clinical Trial.
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.
Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, Sato N. Tanaka Y, et al. Among authors: hirata s. Ann Rheum Dis. 2020 Jan;79(1):94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19. Ann Rheum Dis. 2020. PMID: 31630117 Free PMC article. Clinical Trial.
Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T; SURPRISE study group. Kaneko Y, et al. Among authors: hirata s. Ann Rheum Dis. 2018 Sep;77(9):1268-1275. doi: 10.1136/annrheumdis-2018-213416. Epub 2018 May 31. Ann Rheum Dis. 2018. PMID: 29853455 Free PMC article. Clinical Trial.
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).
Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Saito K, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H. Takeuchi T, et al. Among authors: hirata s. Mod Rheumatol. 2012 Jun;22(3):327-38. doi: 10.1007/s10165-011-0516-6. Epub 2011 Sep 7. Mod Rheumatol. 2012. PMID: 21898074 Free PMC article.
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Tanaka Y, Yamaguchi A, Miyamoto T, Tanimura K, Iwai H, Kaneko Y, Takeuchi T, Amano K, Iwamoto N, Kawakami A, Murakami M, Nishimoto N, Atsumi T, Sumida T, Ohmura K, Mimori T, Yamanaka H, Fujio K, Fujino Y, Saito K, Nakano K, Hirata S, Nakayamada S. Tanaka Y, et al. Among authors: hirata s. Rheumatology (Oxford). 2022 Nov 2;61(11):4273-4285. doi: 10.1093/rheumatology/keac075. Rheumatology (Oxford). 2022. PMID: 35136990 Free PMC article.
Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.
Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T. Kato M, et al. Among authors: hirata s. Mod Rheumatol. 2020 May;30(3):442-449. doi: 10.1080/14397595.2019.1621026. Epub 2019 Jun 7. Mod Rheumatol. 2020. PMID: 31106666 Free article. Clinical Trial.
Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis.
Kaneko Y, Kawahito Y, Kojima M, Nakayama T, Hirata S, Kishimoto M, Endo H, Seto Y, Ito H, Nishida K, Matsushita I, Kojima T, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H. Kaneko Y, et al. Among authors: hirata s. Mod Rheumatol. 2021 Jan;31(1):61-69. doi: 10.1080/14397595.2020.1719607. Epub 2020 Jan 30. Mod Rheumatol. 2021. PMID: 31960737
1,098 results